Neurocrine Biosciences, Inc [NBIX] stock prices are up 2.05% to $145.66 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The NBIX shares have gain 1.43% over the last week, with a monthly amount glided 9.68%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Neurocrine Biosciences, Inc [NASDAQ: NBIX] stock has seen the most recent analyst activity on July 21, 2025, when Truist initiated its Buy rating and assigned the stock a price target of $163. Previously, Goldman started tracking the stock with Buy rating on July 10, 2025, and set its price target to $182. On April 15, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $138 on the stock. RBC Capital Mkts upgraded its rating to a Outperform but stick to its price target of $137 on April 14, 2025. Deutsche Bank initiated its recommendation with a Hold and recommended $138 as its price target on February 11, 2025. In a note dated August 29, 2024, Piper Sandler upgraded an Overweight rating on this stock and boosted its target price from $131 to $159.
The stock price of Neurocrine Biosciences, Inc [NBIX] has been fluctuating between $84.23 and $154.61 over the past year. Currently, Wall Street analysts expect the stock to reach $167 within the next 12 months. Neurocrine Biosciences, Inc [NASDAQ: NBIX] shares were valued at $145.66 at the most recent close of the market. An investor can expect a potential return of 14.65% based on the average NBIX price forecast.
Analyzing the NBIX fundamentals
The Neurocrine Biosciences, Inc [NASDAQ:NBIX] reported sales of 2.51B for trailing twelve months, representing a surge of 16.49%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at 0.2%, Pretax Profit Margin comes in at 0.21%, and Net Profit Margin reading is 0.14%. To continue investigating profitability, this company’s Return on Assets is posted at 0.09, Equity is 0.13 and Total Capital is 0.15. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.16.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Neurocrine Biosciences, Inc [NASDAQ:NBIX]’s Current Ratio is 3.20. Further, the Quick Ratio stands at 3.10, while the Cash Ratio is 0.48. Considering the valuation of this stock, the price to sales ratio is 5.76, the price to book ratio is 5.35 and price to earnings (TTM) ratio is 42.99.
Transactions by insiders
Recent insider trading involved GORMAN KEVIN CHARLES, Director, that happened on Aug 07 ’25 when 0.11 million shares were sold. Director, KEVIN CHARLES GORMAN completed a deal on Aug 07 ’25 to buy 0.11 million shares. Meanwhile, Chief Regulatory Officer Delaet Ingrid sold 457.0 shares on Jul 10 ’25.
